Table 1.

Effects of selected amino acid variations within KIR3DL1/S1 on antibody recognition and HLA binding.

Domain	Position	3DS1a	3DL1a	Effect on antibody staining and HLA bindingb	Reference
D0	58	G	S	DX9 and Z27 binding: reductionc	Sharma et al. (2009)
D0	92	M	V	DX9 and Z27 binding: reductionc	Sharma et al. (2009)
D1	138	W	G	DX9 and Z27 binding: no effectc, reductionc	Sharma et al. (2009), O’Connor et al. (2011)
				Tetramer binding (HLA-B*5701): no effectd	Vivian et al. (2011)
				Tetramer binding (HLA-A*2402): reductionc	O’Connor et al. (2011)
				Tetramer binding (HLA-B*2705): abrogationc	O’Connor et al. (2011)
D1	163	S	P	DX9 and Z27 binding: reductionc, no effectc	Sharma et al. (2009), O’Connor et al. (2011)
				Tetramer binding (HLA-A*2402): abrogationc, reductionc	Sharma et al. (2009), O’Connor et al. (2011)
				Tetramer binding (HLA-B*2705): abrogationc	O’Connor et al. (2011)
D1	166	R	L	DX9 binding: reductionc	Sharma et al. (2009)
				Tetramer binding (HLA-A*2402): abrogationc	Sharma et al. (2009), O’Connor et al. (2011)
				Tetramer binding (HLA-B*5701): reductiond	Vivian et al. (2011)
				Tetramer binding (HLA-B*2705): abrogationc	O’Connor et al. (2011)
D2	199	L	P	DX9 and Z27 binding: no effectc	Sharma et al. (2009)
				Tetramer binding (HLA-A*2402): abrogationc	Sharma et al. (2009)
				Tetramer binding (HLA-B*5701): reductiond	Vivian et al. (2011)

^aAmino acid residue of KIR3DS1*013 and KIR3DL1*015, respectively;

^bTetramers folded with the following peptides: HLA-B*5701: LSSPVTKSF (self-peptide), HLA-A*2402: RYPLTFGW (HIV nef), HLA-B*2705: TSTLQEQIGW (HIV gag);

^cEffect observed when aa introduced in KIR3DL1*015;

^dEffect observed when aa introduced in KIR3DL1*001.